Trial Profile

A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDX 585 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Celldex Therapeutics Inc

Most Recent Events

16 Apr 2025 Planned End Date changed from 1 May 2025 to 1 Dec 2025.
16 Apr 2025 Planned primary completion date changed from 1 May 2025 to 1 Dec 2025.
06 Dec 2024 Planned End Date changed from 1 Feb 2026 to 1 May 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com